Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Advanced materials provide solutions towards a sustainable world.
Hultman L, Mazur S, Ankarcrona C, Palmqvist A, Abrahamsson M, Antti ML, Baltzar M, Bergström L, de Laval P, Edman L, Erhart P, Kloo L, Lundberg MW, Mikkelsen A, Moons E, Persson C, Rensmo H, Rosén J, Rudén C, Selleby M, Sundgren JE, Dick Thelander K, Tybrandt K, Weihed P, Zou X, Åstrand M, Björkman CP, Schneider JM, Eriksson O, Berggren M. Hultman L, et al. Among authors: astrand m. Nat Mater. 2024 Feb;23(2):160-161. doi: 10.1038/s41563-023-01778-9. Nat Mater. 2024. PMID: 38307974 No abstract available.
Population Pharmacokinetic Modeling of Cotadutide: A Dual Agonist Peptide of Glucagon-Like Peptide and Glucagon Receptors Administered to Participants with Type II Diabetes Mellitus, Chronic Kidney Disease, Obesity and Non-Alcoholic Steatohepatitis.
Yu H, Åstrand M, Cheng J, Nitin K, Hamrén B, Khan AA. Yu H, et al. Among authors: astrand m. Clin Pharmacokinet. 2024 Feb;63(2):255-267. doi: 10.1007/s40262-023-01337-0. Epub 2024 Jan 18. Clin Pharmacokinet. 2024. PMID: 38236561
Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial.
Heerspink HJL, Kiyosue A, Wheeler DC, Lin M, Wijkmark E, Carlson G, Mercier AK, Åstrand M, Ueckert S, Greasley PJ, Ambery P. Heerspink HJL, et al. Among authors: astrand m. Lancet. 2023 Nov 25;402(10416):2004-2017. doi: 10.1016/S0140-6736(23)02230-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931629 Clinical Trial.
Correction to "Small Bispecific Affinity Proteins for Simultaneous Target Binding and Albumin-Associated Half-Life Extension".
von Witting E, Lindbo S, Lundqvist M, Möller M, Wisniewski A, Kanje S, Rockberg J, Tegel H, Åstrand M, Uhlén M, Hober S. von Witting E, et al. Among authors: astrand m. Mol Pharm. 2022 Sep 5;19(9):3451. doi: 10.1021/acs.molpharmaceut.2c00655. Epub 2022 Aug 10. Mol Pharm. 2022. PMID: 35947447 Free PMC article. No abstract available.
49 results